Cases pending with drug price liability review committee

516. SHRI UDAY PRATAP SINGH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the details of cases pending with the Drug Price Liability Review Committee; and

(b) the names of the companies and the amount quantified?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI RAM VILAS PASWAN): (a) As on date, there are two cases pending with the Drug Prices Liabilities Review Committee (DPLRC) pertaining to M/s. S.G. Pharmaceuticals Ltd and M/s Geoffry Manners & John Wyeth Ltd. for quantification of DPEA liability of these companies. In addition, there are 26 cases pending with the Committee which cannot be taken up by the DPLRC because of the stay dated 30.6.1997 granted by the Hon'bie Bombay High Court in writ petition filed by the Indian Drugs Manufacturer's Association (IDMA) & others restraining the Department and its committees from determining fresh liabilities.

(b) The names of the companies and the amount quantified by the DPLRC is given in statement.

Statement

Name of the Company and amount of liability quantified by the DPLRC.

(Rs. in lakhs)

SI NO	Name of the Company	Name of the bulk drug	Amount of liability qualified by the DPLRC
(1)	(2)	(3)	(4)
1	M/s Merind Ltd	Dexamethasone	6772.8
2	M/s Biochem Pharma Industries	Rifampicin	99.76
3	M/s Lupin Laboratories	Rifampicin	1065.09
4	M/s Unique Pharmaceuticals	Oxyphenabutazone	591,05
5	M/s Ambalal Sarabhai Enterpises	Amoxycillin Trihydrate	84.13
6	M/s Gufic Ltd	Amoxycillin Trihydrate	73.86
7	M/s Lyka Labs	Ampicillin Trihydrate	70.37
8	M/s Unique Pharma Labs Ltd	Metronidazole	461.47
9	M/s Ranbaxy Laboratories Ltd.	Ampicillin Trihydrate	416.84
10	M/s Lyka Labs	Rifampicin	148.38
11	M/s Lyka Labs Ltd	Ethambutol	38.50
12	M/s Dolphin Labs Ltd	Amoxycillin Trihydrate	51.53

(1)	(2)	(3)	(4)
13	M/s Astra-IDL Ltd	Ibuprofen	174.86
14	M/s Ranbaxy Labs Ltd	Rifampicin	203.00
15	M/s Themis Chemicals	Rifampicin	126.07
16	M/s Cipla Ltd	Metronidazole	22.81
17	M/s Lyka Labs Ltd	Amoxycillin Trihydrate	13.95
18	M/s Knoll Pharmaceutical	Ibuprofen	346.64/57.67@
19	M/s Themis Chemicals	Ethamubtol	200.00
20	M/s Lyka Labs	Fluocinolone Acetonide	1804.65/Nil@
21	M/s Dolphin Labs Ltd	Metronidazole	28.66
22	M/s Tamil Nadu Dadha	Calcium Lactate	130.34/120.90@
23	M/s Boehringer Mannheim (India) Ltd.	Euglucon Tabs	313.17
24	M/s U.S. Vitamins Ltd.	Doxycycline	132.62/125.19@
25	M/s Dolphin Labs Ltd.	Sulphamethaxazole & Trimethoprim	54.20/11.45@
26.	M/s Cyanamid (India) (Now M/s Wyeth Lederle Ltd.)	Dimethyl Chloro-Tetracycline Hydrochloride etc.	4304.16/4274.72@

@There is difference of opinion among Members of DPLRC.

Impact of new Patents Act on domestic Pharmaceutical sector

517. SHRI MANOJ BHATTACHARYA:
SHRI C. RAMACHANDRAIAH:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether the new Patents Act passed recently has made any impact on the domestic pharmaceutical sector;

(b) if so, the details thereof; and

(c) the measures adopted to prevent the anticipated hike in price of life-saying drugs and make them available at affordable prices?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI RAM VILAS PASWAN): (a) and (b) It is too early to know the effect of the new patent regime on the prices of drugs. However, the National Pharmaceutical Pricing Authority has not received any report of abnormal increase in the prices of drugs or their non-availability after the said amendment.

(c) The patent law in the country provides for **a** strong and comprehensive set of safeguards including provisions to ensure